Modulating Movement Intention Via Cortical Stimulation

Korábbi kezelés

• Taking tricyclic antidepressant or antiepileptic medications or CNS active drugs under "strong potential hazard" list in Rossi et al., 2009
• Taking tricyclic antidepressant medications or CNS active drugs under "strong potential hazard" list in Rossi et al., 2009;

Más betegség

• Any history of a significant neurological disorder, which may interfere with the interpretation of study data, as determined by the PI
• Chronic or progressive medical condition
• Any history of traumatic brain injury or significant head trauma
• History of any psychotic disorder or other psychiatric condition which may interfere with data interpretation
• Current diagnosis of any inflammatory or autoimmune disorder within last 6 months
  • PMD and PNES Patients
• Any history of traumatic brain injury or significant head trauma
• Diagnosis of organic seizure disorder, including febrile seizures and tonic-clonic seizures;
• Neurological disorder other than PMD and PNES including stroke, fainting spells or syncope of unknown cause(s);
• Major or unstable medical illness, especially any current diagnosis of inflammatory or autoimmune disorders within last 6 months
• Diagnosis of dementia, or Montreal Cognitive Assessment (MoCA) ≤24;
• History of significant uncontrollable movements of the head;

Egyéb

• Currently meets criteria for substance abuse or dependence
• Pregnancy
• Metal or devices in the head, including neurostimulators or metal foreign bodies
• Any other implanted metal device, including pacemaker, spinal cord stimulator, VNS.
• Any other ferromagnetic substance in the body that may increase study risk (including dental prosthetics, etc.).
• Metal or devices in the head, including neurostimulators or metal foreign bodies
• Recurrent visual hallucinations, within the past 6 months;
• Any clinically significant abnormality on vital signs

• (Healthy Controls)
• Fluent in English
  • (Patients with PMD or PNES):
• Diagnosis of PMD/PNES confirmed by a neurologist with expertise in movement disorders.
• Per the treating neurologist, subject is unlikely to require treatment and/or dosage changes for 3-6 months following screening